A5067991979- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Restless Legs Syndrome Research
- Botulinum Toxin and Related Neurological Disorders
- Autism Spectrum Disorder Research
- Balance, Gait, and Falls Prevention
- Health disparities and outcomes
- Cerebral Palsy and Movement Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Transcranial Magnetic Stimulation Studies
- Dementia and Cognitive Impairment Research
- Genetic Neurodegenerative Diseases
- Dysphagia Assessment and Management
- Ginkgo biloba and Cashew Applications
- Aging, Health, and Disability
- Parkinson's Disease and Spinal Disorders
- Geriatric Care and Nursing Homes
- Sleep and Wakefulness Research
- Voice and Speech Disorders
- Obsessive-Compulsive Spectrum Disorders
- Aging and Gerontology Research
- Health, psychology, and well-being
- Migration, Aging, and Tourism Studies
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Stuttering Research and Treatment
Biomedical Research Networking Center on Neurodegenerative Diseases
2016-2025
Instituto de Salud Carlos III
2015-2025
Parkinson's UK
2024
Centro de Investigación Biomédica en Red
2013-2024
John Wiley & Sons (United States)
2018-2023
Centro Nacional de Epidemiología
2001-2021
Escuela Nacional de Sanidad
2020
Hospital General Yagüe
2017
National Center for Epidemiology
2007-2016
Leiden University Medical Center
2014-2016
We present a clinimetric assessment of the Movement Disorder Society (MDS)-sponsored revision Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The MDS-UDPRS Task Force revised and expanded UPDRS using recommendations from published critique. MDS-UPDRS has four parts, namely, I: Non-motor Experiences Daily Living; II: Motor III: Examination; IV: Complications. Twenty questions are completed by patient/caregiver. Item-specific instructions an appendix complementary additional scales...
Abstract Nonmotor symptoms (NMS) of Parkinson's disease (PD) are not well recognized in clinical practice, either primary or secondary care, and frequently missed during routine consultations. There is no single instrument (questionnaire scale) that enables a comprehensive assessment the range NMS PD both for identification problems measurement outcome. Against this background, multidisciplinary group experts, including patient representatives, has developed an screening questionnaire...
Abstract Background: Non‐motor symptoms are detrimental to health‐related quality of life (HRQoL) Parkinson's disease patients. In this study, the Non‐Motor Symptoms Scale (NMSS) was used assess impact non‐motor on HRQoL Methods: a multicenter, international, cross sectional study 411 patients, NMSS applied along with clinical (Hoehn and Yahr staging SCOPA‐Motor) measures (PDQ‐39, EQ‐5D). Prevalence determined also through NMSS. The association SCOPA‐Motor differences in scores between...
Abstract Our purpose was to verify some basic aspects of validation the Unified Parkinson's Disease Rating Scale (UPDRS). One hundred and sixtyseven disease (PD) patients were included. Group A (n=40) simultaneously assessed by five raters who applied UPDRS other PD rating scales (PDRS). set timed tests, Mini‐Mental State Examination (MMSE), Hamilton for Depression (HSD) administered an independent examiner. B (n = 127) individually through PDRSs one neurologist in four different hospitals....
Abstract 2006, there was, no single instrument (questionnaire or scale) for attempting a comprehensive assessment of the wide range nonmotor symptoms (NMS) Parkinson's disease (PD). The PD group, multidisciplinary group experts including patient representatives developed and validated NMS screening questionnaire (NMSQuest) comprising 30 items. NMSQuest is self completed tool designed to draw attention presence NMS. In this paper, we present results gathered from 545 patients using definitive...
The nonmotor symptoms (NMS) of Parkinson's disease (PD) are less well recognised and can be more troublesome to patients carers than classical motor features. NMS frequently missed during routine consultations such under-recognition may have implications on quality care given that many treatable. To determine the proportion not declaring healthcare professional (HCP) as assessed by self completion questionnaire (NMSQuest), a validated, self-completing with 30 items. Multicentre international...
The previous Parkinson's disease sleep scale (PDSS) is a 15-item visual analogue that assesses the profile of nocturnal disturbances in (PD) patients.To extend so it becomes frequency measure with five categories and encompasses unmet needs such as restless legs syndrome, akinesia, pain, apnea.For validation PDSS-2, PD patients' ratings investigators' interviews were compared to from semistructured interview caregiver/partner, related scales. PDSS-2 was repeated for test-retest-reliability...
Apathy is a common condition in Parkinson's disease (PD) and generally defined as lack of motivation. It associated with more severe cognitive dysfunction decrease activities daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be symptom both depressive apathetic syndromes. The Movement Disorder Society (MDS) commissioned task force assess clinimetric properties apathy anhedonia scales PD patients. A systematic literature review was conducted identify that...
Abstract Switching from oral medications to continuous infusion of levodopa/carbidopa gel reduces motor complications in advanced Parkinson's disease (PD), but effects on nonmotor symptoms (NMSs) are unknown. In this prospective open‐label observational study, we report the intrajejunal NMS PD based standard assessments utilizing scale (NMSS) along with unified rating (UPDRS 3 and 4 complications) quality life (QoL) using questionnaire (PDQ‐8). Twenty‐two patients (mean age 58.6 years,...
Pain is a key unmet need and major aspect of non-motor symptoms Parkinson's disease (PD). No specific validated scales exist to identify grade the various types pain in PD. We report an international, cross-sectional, open, multicenter, one-point-in-time evaluation with retest study first PD-specific scale, King's PD Scale. Its seven domains include 14 items, each item scored by severity (0-3) multiplied frequency (0-4), resulting subscore 0 12, total possible score range from 168. One...
ABSTRACT Subcutaneous apomorphine infusion (Apo) and intrajejunal levodopa (IJLI) are two treatment options for patients with advanced Parkinson's disease (PD) refractory motor complications, varying cost of treatment. There no multicenter studies comparing the effects strategies. This open‐label, prospective, observational, 6‐month, study compared 43 on Apo (48.8% males, age 62.3 ± 10.6 years; duration: 14 4.4 median H & Y stage 3; interquartile range [IQR]: 3‐4) 44 IJLI (56.8% 62.7 9.1...
Existing anxiety rating scales have limited construct validity in patients with Parkinson's disease (PD). This study was undertaken to develop and validate a new scale, the Parkinson Anxiety Scale (PAS), that would overcome limitations of existing scales. The general structure PAS based on outcome Delphi procedure. Item selection canonical correlation analysis Rasch items Hamilton Rating (HARS) Beck Inventory (BAI) from previously published study. Validation done cross-sectional...
Abstract Objective Real‐life observational report of clinical efficacy bilateral subthalamic stimulation (STN‐DBS), apomorphine (APO), and intrajejunal levodopa infusion (IJLI) on quality life, motor, nonmotor symptoms (NMS) in Parkinson's disease (PD). Methods In this prospective, multicenter, international, real‐life cohort observation study 173 PD patients undergoing STN‐DBS (n = 101), IJLI 33), or APO 39) were followed‐up using PDQuestionnaire‐8, NMSScale (NMSS), Unified Rating Scale...
Parkinson's disease is now one of the fastest-growing neurodegenerative disorders in developed world, with an increasing prevalence and associated socioeconomic costs. Progression leads to a gradual deterioration patients' quality life, despite optimal treatment, both medical societal needs increase, often assistance paid and/or unpaid caregivers. We aimed quantify incremental economic burden by severity real-world setting across differing geographic regions. Demographics, clinical...
Abstract Background Impulse‐control and related behavioral disorders (ICBDs) significantly impact the lives of Parkinson's disease (PD) patients caregivers, with lasting consequences if undiagnosed untreated. While ICBD pathophysiology risk factors are well‐studied, a standardized severity definition treatment evidence remain elusive. Objective This work aimed to establish international expert consensus on strategies. To comprehensively address diverse availabilities, experts from various...
Importance Deep brain stimulation of the subthalamic nucleus (STN-DBS) improves quality life (QOL) in patients with advanced Parkinson disease (PD). However, controlled studies more than 3 years follow-up are lacking. Objective To investigate long-term effects STN-DBS on QOL compared standard-of-care medication (MED). Design, Setting, and Participants In this prospective, observational, quasi-experimental, longitudinal nonrandomized trial, 183 were screened for eligibility 167 enrolled from...